Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #5573: New anti-cancer quinoxalinyl-piperazine compounds: G2/M-specific microtubule inhibitor

Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn and Young-Dae Kong
Young Bok Lee
Rexahn Pharmaceutical, Inc., Rockville, MD; KRICT, Taejon, Korea, Republic of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deog Joong Kim
Rexahn Pharmaceutical, Inc., Rockville, MD; KRICT, Taejon, Korea, Republic of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chang-Ho Ahn
Rexahn Pharmaceutical, Inc., Rockville, MD; KRICT, Taejon, Korea, Republic of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young-Dae Kong
Rexahn Pharmaceutical, Inc., Rockville, MD; KRICT, Taejon, Korea, Republic of
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

A series of novel quinoxalinyl-piperazine compounds, 1-[(substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives were synthesized and evaluated as an anti-cancer-agent. From screening of quinoxalinyl-piperazine compound library, we identified that many compounds inhibited proliferation of various human cancer cells at nanomolar concentrations. Among them, one of the fluoro quinoxalinyl-piperazine derivatives showed its IC50 values ranging from 0.011 uM to 0.025 uM in the growth inhibition of cancer cells. This compound also displayed a more potent effect against gemcitabine, paclitaxel or cisplatin-resistant cancer cell lines than the original cytotoxic cancer drugs. The potency of this novel compound was further confirmed with the synergistic cytotoxic effect with several known cancer drugs such as paclitaxel, doxorubicin, cisplatin, gemcitabine or 5-fluorouracil in cancer cells. This strong cell killing effect was derived from the induction of apoptosis. Mechanistic studies have shown that the quinoxalinyl-piperazine compound is a G2/M-specific cell cycle inhibitor and inhibits tubulin polymerization with p21 induction by a unique mechanism. This suggests that the anticancer mechanism of this compound is quite different from that of paclitaxel that is a microtubule stabilizer and the quinoxalinyl-piperazine compound is a unique and new therapeutic anti-cancer drug candidate. This compound inhibited the growth of various human tumors in mouse xenograft models, including renal and pancreas human tumors after oral administration. Pharmacokinetic studies in animal showed good oral bioavailability and no significant accumulation when given intravenously and orally.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5573.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #5573: New anti-cancer quinoxalinyl-piperazine compounds: G2/M-specific microtubule inhibitor
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #5573: New anti-cancer quinoxalinyl-piperazine compounds: G2/M-specific microtubule inhibitor
Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn and Young-Dae Kong
Cancer Res May 1 2009 (69) (9 Supplement) 5573;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #5573: New anti-cancer quinoxalinyl-piperazine compounds: G2/M-specific microtubule inhibitor
Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn and Young-Dae Kong
Cancer Res May 1 2009 (69) (9 Supplement) 5573;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Novel Agents 4 -- Poster Presentations - Proffered Abstracts

  • Abstract #5575: Vanadium: A possible chemotherapeutic agent against astrocytomas
  • Abstract #5579: The inhibitory effects of organoselenium compounds on mTOR signaling in prostate cancer cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement